Integrating Innate Immunity into a Global “Systems” Context: The Complement Paradigm Shift - Systems Biology: Networks, Models, and Applications - page 186

26. Soulika, A. M., M. M. Khan, T. Hattori, et al. Inhibition of heparin/protamine

complex-induced complement activation by compstatin in baboons.
Clinical Immunology , 96(3):212-21, 2000.

27. Nilsson, B., R. Larsson, J. Hong, et al. Compstatin inhibits complement and

cellular activation in whole blood in two models of extracorporeal circula-
tion. Blood , 92(5):1661-7, 1998.

28. Fiane, A. E., T. E. Mollnes, V. Videm, et al. Prolongation of ex vivo-perfused

pig xenograft survival by the complement inhibitor compstatin.
Transplantation Proceedings , 31(1-2):934-5, 1999.

29. Fiane, A. E., T. E. Mollnes, V. Videm, et al. Compstatin, a peptide inhibitor

of C3, prolongs survival of ex vivo perfused pig xenografts.
Xenotransplantation , 6:52-65, 1999.

30. Fiane, A. E., V. Videm, J. D. Lambris, et al. Modulation of fluid-phase com-

plement activation inhibits hyperacute rejection in a porcine-to-human
xenograft model. Transplantation Proceedings , 32(5):899-900, 2000.

31. Mollnes, T. E., O. L. Brekke, M. Fung, et al. Essential role of the C5a recep-

tor in E. coli -induced oxidative burst and phagocytosis revealed by a novel
lepirudin-based human whole blood model of inflammation. Blood ,
100(5):1869-77, 2002.

32. Klegeris, A., E. A. Singh and P. L. McGeer. Effects of C-reactive protein and

pentosan polysulphate on human complement activation. Immunology ,
106(3):381-8, 2002.

33. Furlong, S. T., A. S. Dutta, M. M. Coath, et al. C3 activation is inhibited by

analogs of compstatin but not by serine protease inhibitors or peptidyl
alpha-ketoheterocycles. Immunopharmacology , 48(2):199-212, 2000.

34. Sahu, A., D. Morikis and J. D. Lambris. Compstatin, a peptide inhibitor of

complement, exhibits species-specific binding to complement component
C3. Molecular Immunology , 39(10):557-66, 2003.

35. Morikis, D., N. Assa-Munt, A. Sahu, et al. Solution structure of compstatin,

a potent complement inhibitor. Protein Science , 7(3):619-27, 1998.

36. Morikis, D., A. Sahu, W. T. Moore and J. D. Lambris. Design, structure,

function and application of compstatin. In J. Matsukas and T.
Mavromoustakos (Eds.), Bioactive Peptides in Drug Discovery and Design:
Medical Aspects (pp. 235-46). Ios Press, Amsterdam, 1999.

37. Sahu, A., A. M. Soulika, D. Morikis, et al. Binding kinetics, structure-activ-

ity relationship, and biotransformation of the complement inhibitor
compstatin. Journal of Immunology , 165(5):2491-9, 2000.

38. Furlong, S. T., A. S. Dutta, M. M. Coath, et al. C3 activation is inhibited by

analogs of compstatin but not by serine protease inhibitors or peptidyl
alpha-ketoheterocycles. Immunopharmacology 48(2):199-212, 2000.

39. Morikis, D., M. Roy, A. Sahu, et al. The structural basis of compstatin activ-

ity examined by structure-function-based design of peptide analogs and
NMR. Journal of Biological Chemistry , 277(17):14942-53, 2002.

40. Soulika, A. M., D. Morikis, M. R. Sarrias, et al. Studies of structure-activity

relations of complement inhibitor compstatin. Journal of Immunology ,
171(4):1881-90, 2003.

41. Sahu, A., A. M. Soulika, D. Morikis, et al. Binding kinetics, structure-activity

relationship, and biotransformation of the complement inhibitor comp-
statin. Journal of Immunology , 165(5):2491-9, 2000.